Pharmaron Beijing (HKG:3759, SHE:300759) posted an attributable net profit of 750.2 million yuan for the first half of 2026, up 7% from 701.4 million yuan a year earlier.
Earnings per share stood at 0.4113 yuan, compared with 0.3978 yuan in the year-ago period, according to a Thursday Hong Kong bourse filing.
Revenue increased 18% year over year to 7.60 billion yuan from 6.44 billion yuan.